Leal Health Launches AI-Powered Predictive Patient Journey Platform

Leal Health, formerly known as Trialjectory, an AI-powered decision support platform that democratizes patient access to advanced cancer treatments and empowers the pharmaceutical and biotech industry to execute patient-centric clinical trials, announced that it has launched a predictive patient journey offering to 1) help cancer patients navigate their treatment journey at all stages of the disease, 2) educate patients and their oncologists on all of their treatment options in a timely manner to remove barriers to care in advance, and 3) enable the pharmaceutical industry to identify potential patients that could match to their trials in the future.

With this groundbreaking new technology, Leal leverages its AI-based platform to preemptively match cancer patients with available treatment options that could be relevant for them in the future should their disease progress. At the same time, Leal gives pharmaceutical companies and clinical trial sponsors insight into patients who have a high probability of participating in future trials due to their disease state. For example, trial sponsors now have specific insight into how minority and underrepresented patients' cancer changes over time and how patients can adjust current treatments to remain eligible for other clinical trials. This marks the first time that pharmaceutical companies are able to track, understand and predict a patient's cancer journey from start to finish.

Continue reading this story here.